JP7554180B2 - Ｃ－ｃケモカイン受容体４（ｃｃｒ４）拮抗薬および１種以上のチェックポイント阻害剤を用いる併用療法 - Google Patents

Ｃ－ｃケモカイン受容体４（ｃｃｒ４）拮抗薬および１種以上のチェックポイント阻害剤を用いる併用療法 Download PDF

Info

Publication number
JP7554180B2
JP7554180B2 JP2021510337A JP2021510337A JP7554180B2 JP 7554180 B2 JP7554180 B2 JP 7554180B2 JP 2021510337 A JP2021510337 A JP 2021510337A JP 2021510337 A JP2021510337 A JP 2021510337A JP 7554180 B2 JP7554180 B2 JP 7554180B2
Authority
JP
Japan
Prior art keywords
alkyl
ctla
group
cancer
ccr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021510337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021536442A (ja
Inventor
リー シーチエ
レディ マリ ベンカット
シン ラジンダー
チュイ ヤン
チャン ペングリー
Original Assignee
ケモセントリックス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケモセントリックス，インコーポレイティド filed Critical ケモセントリックス，インコーポレイティド
Publication of JP2021536442A publication Critical patent/JP2021536442A/ja
Application granted granted Critical
Publication of JP7554180B2 publication Critical patent/JP7554180B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021510337A 2018-08-29 2019-08-28 Ｃ－ｃケモカイン受容体４（ｃｃｒ４）拮抗薬および１種以上のチェックポイント阻害剤を用いる併用療法 Active JP7554180B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862724412P 2018-08-29 2018-08-29
US62/724,412 2018-08-29
US201862771853P 2018-11-27 2018-11-27
US62/771,853 2018-11-27
PCT/US2019/048461 WO2020047030A1 (en) 2018-08-29 2019-08-28 Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors

Publications (2)

Publication Number Publication Date
JP2021536442A JP2021536442A (ja) 2021-12-27
JP7554180B2 true JP7554180B2 (ja) 2024-09-19

Family

ID=69639506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510337A Active JP7554180B2 (ja) 2018-08-29 2019-08-28 Ｃ－ｃケモカイン受容体４（ｃｃｒ４）拮抗薬および１種以上のチェックポイント阻害剤を用いる併用療法

Country Status (16)

Country Link
US (2) US11446289B2 (enExample)
EP (1) EP3843734B1 (enExample)
JP (1) JP7554180B2 (enExample)
KR (1) KR102817790B1 (enExample)
CN (1) CN112601526B (enExample)
AU (1) AU2019327430B2 (enExample)
BR (1) BR112021002928A2 (enExample)
CA (1) CA3109498A1 (enExample)
ES (1) ES3064498T3 (enExample)
IL (1) IL280831B2 (enExample)
MA (1) MA53503A (enExample)
MX (1) MX2021002302A (enExample)
SG (1) SG11202101454PA (enExample)
TW (1) TWI888358B (enExample)
WO (1) WO2020047030A1 (enExample)
ZA (1) ZA202101055B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6141864B2 (ja) 2011-12-01 2017-06-07 ケモセントリックス，インコーポレイティド Ｃｃｒ（４）アンタゴニストとしての置換アニリン
ES3064498T3 (enExample) * 2018-08-29 2026-04-27 Chemocentryx Inc
KR20230149729A (ko) * 2022-04-19 2023-10-27 케모센트릭스, 인크. Ccr4 길항제

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500242A (ja) 2011-12-01 2015-01-05 ケモセントリックス，インコーポレイティド Ｃｃｒ（４）アンタゴニストとしての置換アニリン
JP2016520548A (ja) 2013-04-03 2016-07-14 アイビーシー ファーマスーティカルズ，インコーポレイテッド 疾患に対する免疫反応を誘導するための併用療法
JP2017538680A (ja) 2014-11-05 2017-12-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
WO2018005374A1 (en) 2016-06-27 2018-01-04 Chemocentryx, Inc. Immunomodulator compounds
WO2018022992A1 (en) 2016-07-29 2018-02-01 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
WO2018101448A1 (en) 2016-11-30 2018-06-07 Kyowa Hakko Kirin Co., Ltd. Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US20020173524A1 (en) * 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
AU2003256923A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
JP2007210887A (ja) 2004-06-21 2007-08-23 Astellas Pharma Inc 縮合二環性ピリミジン誘導体
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
JP2009148309A (ja) 2007-12-18 2009-07-09 Uni Charm Corp 吸収性物品
US8263073B2 (en) 2008-02-04 2012-09-11 Medarex, Inc. Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
JP5523572B2 (ja) 2009-10-26 2014-06-18 中国石油化工股▲ふん▼有限公司 担持型非メタロセン触媒、その製造方法およびその使用
WO2011050565A1 (zh) 2009-10-26 2011-05-05 中国石油化工股份有限公司 负载型非茂金属催化剂、其制备方法及其应用
WO2011056423A2 (en) 2009-10-28 2011-05-12 Exxonmobil Chemical Patents Inc. Catalyst compounds and use thereof
US8952113B2 (en) 2009-11-13 2015-02-10 China Petroleum & Chemical Corp. Supported nonmetallocene catalyst, preparation and use thereof
EP2500364B1 (en) 2009-11-13 2020-03-04 China Petroleum & Chemical Corporation Supported non-metallocene catalyst preparation method and application thereof
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
WO2016181349A1 (en) * 2015-05-14 2016-11-17 Pfizer Inc. Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
TW201713332A (zh) * 2015-07-14 2017-04-16 協和醱酵麒麟有限公司 包含與抗體組合投予之ｉｄｏ抑制物之腫瘤治療劑
TWI724056B (zh) * 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
ES3064498T3 (enExample) * 2018-08-29 2026-04-27 Chemocentryx Inc

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500242A (ja) 2011-12-01 2015-01-05 ケモセントリックス，インコーポレイティド Ｃｃｒ（４）アンタゴニストとしての置換アニリン
JP2016520548A (ja) 2013-04-03 2016-07-14 アイビーシー ファーマスーティカルズ，インコーポレイテッド 疾患に対する免疫反応を誘導するための併用療法
JP2017538680A (ja) 2014-11-05 2017-12-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
WO2018005374A1 (en) 2016-06-27 2018-01-04 Chemocentryx, Inc. Immunomodulator compounds
WO2018022992A1 (en) 2016-07-29 2018-02-01 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
WO2018101448A1 (en) 2016-11-30 2018-06-07 Kyowa Hakko Kirin Co., Ltd. Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.Med.Chem.，Vol.60，2017年，pp.5857-5867

Also Published As

Publication number Publication date
CA3109498A1 (en) 2020-03-05
ZA202101055B (en) 2025-08-27
NZ773164A (en) 2025-07-25
US12011439B2 (en) 2024-06-18
WO2020047030A1 (en) 2020-03-05
KR20210053306A (ko) 2021-05-11
EP3843734B1 (en) 2026-01-28
TWI888358B (zh) 2025-07-01
US20230097128A1 (en) 2023-03-30
TW202023555A (zh) 2020-07-01
MX2021002302A (es) 2021-04-28
IL280831B2 (en) 2024-05-01
JP2021536442A (ja) 2021-12-27
US11446289B2 (en) 2022-09-20
SG11202101454PA (en) 2021-03-30
MA53503A (fr) 2021-07-07
AU2019327430A1 (en) 2021-03-18
AU2019327430B2 (en) 2024-10-03
EP3843734C0 (en) 2026-01-28
EP3843734A1 (en) 2021-07-07
BR112021002928A2 (pt) 2021-05-11
IL280831B1 (en) 2024-01-01
CN112601526B (zh) 2025-10-03
EP3843734A4 (en) 2022-05-25
CN112601526A (zh) 2021-04-02
US20200069673A1 (en) 2020-03-05
ES3064498T3 (enExample) 2026-04-27
KR102817790B1 (ko) 2025-06-05
IL280831A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
JP7337833B2 (ja) 縮合二環式Ｃ５ａＲアンタゴニストのプロドラッグ
KR102852027B1 (ko) C5aR 억제제로서의 디아릴 치환된 5,5-융합 고리 화합물
DK3041827T3 (en) 1,2,4-OXADIAZOLD DERIVATIVES AS IMMUNE MODULATORS
ES2816060T3 (es) Aza-aril 1H-pirazol-1-il-bencenosulfonamidas como antagonistas de CCR(9)
KR102736360B1 (ko) C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물
US12011439B2 (en) Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
JP7453139B2 (ja) ケモカイン受容体２（ｃｃｒ２）アンタゴニスト及びｐｄ－１／ｐｄ－ｌ１阻害剤を使用した併用療法
EP3474845A1 (en) Immunomodulator compounds
US20240115682A1 (en) Methods of treating cancer using heteroaryl-biphenyl amide derivatives
TW201803850A (zh) 可溶性C5aR拮抗劑
TW201938160A (zh) 以ccr2拮抗劑治療實體腫瘤的方法
RU2810717C2 (ru) Комбинированная терапия с использованием антагонистов c-c хемокинового рецептора 4 (ccr4) и одного или более ингибиторов контрольных точек
EA048430B1 (ru) Способы комбинированной терапии
EA049712B1 (ru) Способы лечения рака с использованием производных гетероарилбифениламида
HK40000508B (en) 2-oxindole compounds

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240827

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240906

R150 Certificate of patent or registration of utility model

Ref document number: 7554180

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150